Review
Version 1
Preserved in Portico This version is not peer-reviewed
Harnessing NKG2D CAR-T Cell Therapy to Target Solid Tumors: Advancements and Applications
Version 1
: Received: 19 January 2024 / Approved: 23 January 2024 / Online: 23 January 2024 (07:43:32 CET)
How to cite: Chasov, V.; Rizvanov, A. Harnessing NKG2D CAR-T Cell Therapy to Target Solid Tumors: Advancements and Applications. Preprints 2024, 2024011661. https://doi.org/10.20944/preprints202401.1661.v1 Chasov, V.; Rizvanov, A. Harnessing NKG2D CAR-T Cell Therapy to Target Solid Tumors: Advancements and Applications. Preprints 2024, 2024011661. https://doi.org/10.20944/preprints202401.1661.v1
Abstract
Here we explore the emerging role of NKG2D CAR-T cell therapy in the realm of solid tumor treatment. Unique capabilities of NKG2D CAR-T cells to recognize stress-induced ligands on cancer cells are discussed, highlighting the therapy's potential for targeted and precise antitumor responses. We also examine the challenges and opportunities associated with NKG2D CAR-T cell therapy, emphasizing the ongoing advancements and clinical trial progress shaping its future. Ultimately, the discussion underscores the transformative promise of NKG2D CAR-T cell therapy in revolutionizing the landscape of solid tumor treatment and enhancing the prospects for improved patient outcomes.
Keywords
Immunotherapy; cell therapy; CAR-T cells; chimeric antigen receptor; NKG2D
Subject
Biology and Life Sciences, Cell and Developmental Biology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment